VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Given Consensus Recommendation of “Reduce” by Brokerages

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have earned a consensus recommendation of “Reduce” from the five ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $0.95.

Several brokerages have recently commented on VTGN. Wall Street Zen upgraded VistaGen Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Maxim Group reiterated a “hold” rating on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Stifel Nicolaus downgraded VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price target for the company. in a report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of VistaGen Therapeutics in a report on Wednesday, January 21st. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $0.90 price objective (down from $15.00) on shares of VistaGen Therapeutics in a research report on Wednesday, December 17th.

Institutional Investors Weigh In On VistaGen Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE increased its position in shares of VistaGen Therapeutics by 1,068.0% in the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock valued at $62,000 after acquiring an additional 19,331 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of VistaGen Therapeutics in the first quarter valued at about $25,000. Marshall Wace LLP acquired a new position in shares of VistaGen Therapeutics in the second quarter valued at about $69,000. Stempoint Capital LP lifted its holdings in shares of VistaGen Therapeutics by 2.0% during the second quarter. Stempoint Capital LP now owns 2,413,254 shares of the company’s stock worth $4,827,000 after purchasing an additional 46,700 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of VistaGen Therapeutics during the second quarter worth about $190,000. 78.39% of the stock is currently owned by institutional investors and hedge funds.

VistaGen Therapeutics Price Performance

Shares of VTGN stock traded up $0.00 during mid-day trading on Monday, hitting $0.59. 212,302 shares of the stock traded hands, compared to its average volume of 1,163,577. VistaGen Therapeutics has a 52-week low of $0.43 and a 52-week high of $5.14. The stock has a market cap of $23.34 million, a P/E ratio of -0.31 and a beta of 0.32. The stock’s fifty day moving average is $0.62 and its two-hundred day moving average is $2.64.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings data on Thursday, February 12th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.06. The firm had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.14 million. As a group, equities analysts forecast that VistaGen Therapeutics will post -1.77 EPS for the current fiscal year.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.